FDA Panel Votes Against Broad Talazoparib-Enzalutamide Label in Prostate Cancer

(MedPage Today) -- An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic castration-resistant prostate cancer...